Can-Fite BioPharma Ltd. announced that its research on Namodenoson, an anti-cancer drug candidate, will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium from January 23-25. Currently, ...
Primary Safety Endpoint Demonstrated to Date; Top-Line Efficacy Data Expected in Q3 2026Ramat Gan, Israel, Jan. 20, 2026 ...
Can-Fite BioPharma Ltd. has announced FDA approval for compassionate use of its anti-cancer drug Namodenoson for a U.S. pancreatic cancer patient. This approval allows the physician to provide the ...
The agreement has been signed upon successful conclusion of a clinical study in dogs with osteoarthritis RAMAT GAN, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: ...
Ramat Gan, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory ...
RAMAT GAN, Israel, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs ...
RAMAT GAN, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and ...
StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a research report sent to investors on Wednesday. The firm issued a sell rating on the stock. Other equities ...
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that ...
Hosted on MSN
Can-Fite BioPharma - Depositary receipt (CANF) price target decreased by 17.42% to 3.46
) has been revised to $3.46 / share. This is a decrease of 17.42% from the prior estimate of $4.19 dated November 9, 2025. The price target is an average of many targets provided by analysts. The ...
Detailed price information for Can-Fite Biopharma Ltd ADR (CANF-A) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results